Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)
Steven M. Opal(Brown University), Gordon R. Bernard(Vanderbilt University Medical Center), Ross Freebairn(Hawke's Bay Hospital), Gary Garber(University of Ottawa), Gary T. Kinasewitz(University of Oklahoma Health Sciences Center), Howard Levy(Apple (Israel)), Delores E. Graham(Eli Lilly (United States)), Dennis G. Maki(University of Wisconsin–Madison), Steven P. LaRosa(Eli Lilly (United States)), Jean-François Dhainaut(Université Paris Cité), Mark D. Williams(English Institute of Sport), S. Betty Yan(Cardiovascular Institute Hospital), David R. Nelson(Eli Lilly (United States))
Cited by 192
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k